Integrative Strategies for Hormone Therapy Optimization

Hormone Optimization, Menopause Care, and Integrative Chiropractic Strategies: A First-Person Clinical Guide

Abstract

As a clinician practicing at the intersection of endocrinology, functional medicine, and integrative chiropractic care, I see how shifts in hormones reverberate through mood, energy, sleep, pain, and metabolism. In this educational post, I walk you through an evidence-informed, first-person roadmap for optimizing testosterone, estradiol, and progesterone in individuals while aligning the musculoskeletal and autonomic systems to support lasting change. I explain how nocturnal awakenings, anxiety, low libido, weight resistance, and chronic pain often reflect neuroendocrine signals. I present practical dosing logic for pellets, injectables, transdermals, sublinguals, and orals; when clomiphene makes sense for men who want to preserve fertility; and why oral micronized progesterone is a linchpin for sleep and endometrial protection. You will see how I “start low and go slow,” use validated symptom scales, and time labs to pharmacokinetics, all while illustrating how integrative chiropractic care reduces sympathetic overdrive and pain, improves HPA axis tone, and accelerates recovery.

Introduction

My Clinical Goal: Calm the Physiology, Then Build Resilience

When patients arrive in my clinic—often exhausted, anxious, and frustrated—I aim to stabilize the terrain first, then guide a stepwise ascent toward resilience. As a DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I integrate endocrine care with chiropractic neuromusculoskeletal methods to reduce pain and sympathetic load while restoring hormone signaling. My approach is simple and humane:

• Stabilize sleep, stress, and movement before “stacking” multiple hormones.
• Measure what matters at baseline and use validated symptom instruments consistently.
• Layer therapies gradually so we can see cause and effect clearly.
• Integrate chiropractic care to normalize autonomic tone and pain pathways, thereby improving endocrine response.

Why Hormone Symptoms Are Neuroendocrine Signals

Understanding Mood, Sleep, Energy, and Focus

When someone tells me their mood feels “off the rails,” their sleep collapses around 2:00–4:00 AM, and focus evaporates by mid-afternoon, I hear neuroendocrine signals. The brain is exquisitely sensitive to gonadal steroids:

• Estradiol enhances serotonergic and dopaminergic tone, stabilizing mood and executive function (Barth et al., 2015).
• Progesterone is a GABAergic neurosteroid; it reduces limbic hyperexcitability and improves sleep onset and continuity (Schmidt et al., 2017).
• Testosterone supports prefrontal motivation and slow-wave sleep; deficits in these processes correlate with anxiety and reduced sleep efficiency (Barrett-Connor et al., 2008; Andersen & Tufik, 2018).

In women—especially in perimenopause and menopause—low progesterone and variable estradiol contribute to nocturnal awakenings and fragmented sleep (Baker et al., 2018; de Zambotti et al., 2015). In men, hypogonadism often presents with early-morning awakenings, diminished libido, and daytime fatigue (Andersen & Tufik, 2018).

Why it matters: disrupted melatonin–cortisol rhythms, nocturnal gluconeogenic stress, and impaired HPA resiliency can produce the classic 2:00–4:00 AM awakening pattern. Recognizing this physiology allows us to correct the signals rather than blame willpower.

Integrative chiropractic fit: By reducing nociceptive drive through targeted spinal manipulation and soft-tissue care, we downshift sympathetic arousal, improve HPA axis tone, and support circadian recalibration. Breathing retraining, light timing, and sleep hygiene complete the circuit.

Perimenopause and the Luteal Gap

Why the Forties Feel Different

In the forties, many women develop a luteal-phase progesterone deficit with relatively preserved or variable estradiol levels. This estrogen–progesterone imbalance produces irritability, sleep-onset difficulty, anxiety, breast tenderness, and dysfunctional uterine bleeding (Schmidt et al., 2017).

• Progesterone is calming and sleep-promoting via GABA-A modulation.
• Inadequate luteal progesterone leads to PMS/PMDD-like symptoms and midlife insomnia.
• Heavy, clotting periods often reflect insufficient progesterone restraint of endometrial proliferation.

When systemic estrogen is used postmenopausally, oral micronized progesterone at night (often 200 mg in non-cycling women) provides reliable endometrial protection and improves sleep quality (Stute et al., 2016; NAMS, 2022). After prolonged hypoestrogenism, receptor sensitivity is heightened—so I start low and go slow to minimize breast tenderness, spotting, and fluid retention.

Loss of Drive, Low Libido, and Metabolic Shifts

The Androgen and Estrogen Story

Both sexes experience low desire and metabolic drag when sex hormones fall:

• In men, testosterone insufficiency presents with reduced morning erections, low libido, decreased motivation, and loss of lean mass (Corona et al., 2012).
• In women, low free testosterone and low estradiol can reduce arousal, lubrication, and orgasmic potential; perimenopausal variability adds vasomotor and mood symptoms (Kingsberg et al., 2019).
• Estradiol supports insulin sensitivity and adipocyte function; loss of estradiol increases hepatic gluconeogenesis and shifts fat distribution (Morsink et al., 2020).
• Testosterone supports muscle mitochondrial biogenesis; low levels reduce basal metabolic rate and raise fat mass (Grossmann, 2018).

Clinical observation: Across my practice, patients with combined hypogonadism and poor sleep show disproportionately impaired training recovery, persistent myofascial tenderness, and weight resistance. When we restore androgen/estrogen balance and improve sleep plus movement quality, body composition and pain thresholds improve reliably.

Why Layering Beats “Turning Everything On”

My Stepwise Protocol and Rationale

All individuals are sensitive to simultaneous shifts across multiple axes. If I start testosterone, estradiol, progesterone, thyroid support, DHEA, and supplements all at once, something often goes wrong—and we cannot tell which change triggered the problem. I use a layered approach:

• Stabilize sleep and stress inputs first with circadian hygiene, anti-inflammatory nutrition, and autonomic balancing.
• Initiate the primary hormone lever with clear outcome measures (Menopause Rating Scale, AIMS scale; Cano et al., 2012).
• Add secondary supports only after we have observed and documented the first change.

This respects physiological timing and avoids receptor overshoot. Neuroendocrine networks rely on pulsatility and feedback loops; excessive inputs can desynchronize clock genes and increase sympathetic tone (Santoro et al., 2015).

Starting With Testosterone to Prime Receptors

Why AR Priming Helps

In many symptomatic women, I begin with carefully dosed bioidentical testosterone to prime androgen receptors (AR), support lean mass, and modestly enhance local aromatase conversion to estradiol in target tissues. This phase often improves energy, libido, mood, and exercise tolerance. When the system responds, I then layer estradiol and progesterone, using very low basal estradiol in perimenopause and steady transdermal estradiol in postmenopause as indicated, with oral micronized progesterone to protect the endometrium and support sleep (Stuenkel et al., 2015; NAMS, 2022).

• AR binding enhances transcription of mitochondrial and anabolic genes.
• Low, steady signaling reduces neurobehavioral oscillations.
• Gradual layering clarifies which agent is most beneficial and minimizes side effects.

Validated Symptom Instruments and Baseline Labs

Measuring What Matters

I obtained the Menopause Rating Scale (MRS) and the AIMS scale at baseline and again at follow-up. These validated tools help patients “see the shift” in their scores, improving shared decision-making and documentation (Cano et al., 2012).

Baseline labs without stopping HRT (if already on therapy) prevent destabilization. My basic panel includes total and free testosterone (prefer direct free), thyroid function, CBC/CMP, and, when indicated, DHEA-S, ferritin/iron indices, fasting insulin/glucose/A1c, hs-CRP, lipids, and vitamin D. For men, I add PSA and hematocrit. Binding dynamics matter: SHBG can profoundly alter bioavailable testosterone; direct free testosterone often better reflects active hormone than calculated estimates (Bhasin et al., 2018).

Perimenopause Strategy

Low Basal Estradiol to Smooth Swings

Perimenopause features estradiol volatility and inconsistent ovulation. Vasomotor symptoms spike on rapid estrogen drops. A low basal estradiol—delivered via patch or pellet at conservative exposure—reduces trough amplitude, stabilizing hypothalamic thermoregulation and sympathetic overactivation (Santoro et al., 2015; NAMS, 2022). I track FSH as a medium-term index of central estrogenization: rather than normalizing immediately, I set a trajectory—roughly halving a very high FSH level over the first cycle, then gradually approaching comfort ranges —while prioritizing symptom relief.

Delivery Modalities

Pellets, Injections, Transdermals, Sublinguals, and Orals

Each route carries distinct pharmacokinetics and trade-offs:

• Pellets: Provide steady-state delivery for 3–5 months, reducing peaks and troughs. Downsides include limited reversibility and prolonged nuisance side effects if they occur. Differences in pressing orientation, density, excipients, and manufacturing influence dissolution kinetics. I favor pellets for convenience-focused patients with prior tolerance who accept less flexibility. For women sensitive to androgenic effects, I consider lower dosing or alternative routes.
• Injections: Weekly or biweekly testosterone cypionate or enanthate remains common in men at 100–200 mg weekly, titrated to symptoms and troughs (Bhasin et al., 2018). Daily microdosing subcutaneously can smooth peaks and reduce erythrocytosis and mood swings, though depot esters may form local nodules; rotate sites and massage gently. In women, I reserve very low-dose divided regimens due to a higher risk of androgenic side effects.
• Transdermal creams and gels: Site matters. Thin, vascularized skin (scrotal or labial) absorbs better and can yield more consistent levels than thicker skin; alcohol-based commercial gels may burn on genital tissue, so I prefer non-alcohol compounded bases for those applications (Kresch et al., 2018). Serum monitoring requires standardized timing and careful technique to avoid contamination; I anchor titration to changes in symptoms.
• Transdermal estradiol patches: Reliable, insurance-friendly, and favorable cardiometabolic profile via avoidance of first-pass hepatic metabolism (Canonico et al., 2016; NAMS, 2022). I start low in women more than a decade postmenopause due to receptor sensitivity, titrating by vasomotor symptoms, sleep, and mood.
• Sublingual/buccal tablets: By bypassing first-pass metabolism, sublingual estradiol and rapid-dissolve testosterone can provide precise, short-acting titration—useful for sensitive women or micro-adjustments. I avoid oral methylated testosterones due to hepatic strain.
• Oral estradiol and oral micronized progesterone: While current guidance favors transdermal estradiol for risk profiles, I use oral micronized progesterone at night for endometrial protection and sleep benefits (Stute et al., 2016; NAMS, 2022). Topical progesterone creams are not sufficiently reliable for endometrial opposition.

Clomiphene for Men

Preserving Fertility While Improving Androgen Signaling

For younger men with robust hypothalamic–pituitary reserve, clomiphene citrate can increase endogenous LH/FSH levels to stimulate testicular testosterone production—particularly valuable when fertility preservation is a priority (Patel et al., 2019). With aging, LH signaling often wanes, and clomiphene’s response may blunt; direct testosterone replacement becomes more practical. I monitor for moodiness or visual symptoms and align the plan with fertility goals.

Chronic Pain, Fibromyalgia, and Hormones

The Inflammation–Endocrine Axis

Chronic pain syndromes, including fibromyalgia, frequently coexist with hormone imbalance. Mechanistically:

• Low estradiol reduces endogenous opioid tone and increases central pain sensitivity (Bartley & Fillingim, 2013).
• Low testosterone correlates with increased pro-inflammatory cytokines, reduced muscle mass, and heightened nociception (Traish, 2018).
• Optimizing sex hormones improves sleep continuity, descending pain inhibition, and muscle metabolism, creating an analgesic virtuous cycle.

Integrative chiropractic fit: I combine graded spinal manipulation, myofascial release, targeted breathing, and progressive loading to normalize mechanoreceptor input and reduce central sensitization. Anti-inflammatory nutrition (omega-3s, polyphenols, fiber, protein distribution) and circadian repair amplify relief. In my clinics, adding targeted hormone therapy often accelerates recovery in otherwise refractory cases.

Vasomotor Symptoms and Night Sweats

Endocrine Thermoregulation

Night sweats are closely linked to estrogen withdrawal and hypothalamic thermoregulatory instability. Transdermal estradiol or, in selected cases, pellets reduce vasomotor symptoms by stabilizing serotonergic and noradrenergic activity in the preoptic area (Thurston et al., 2015). In men, nocturnal sweating may reflect hypogonadism or excessive aromatization; balancing testosterone while monitoring estradiol and improving body composition reduces these complaints.

Sensitive Responders and Anxiety

Choose Controllable Modalities

For patients who identify as highly sensitive or who have high anxiety, I prefer short-acting and controllable modalities (gels, patches) so they can self-adjust or discontinue quickly if needed. Perceived control reduces sympathetic arousal and improves adherence. I start lower, extend titration intervals, use symptom journaling, and leverage wearable data (sleep, HRV, temperature) to guide micro-adjustments (Stuenkel et al., 2015; NAMS, 2023).

SHBG as a Compass

Dosing Testosterone Intelligently

SHBG modulates free testosterone—high SHBG binds more testosterone and lowers bioavailability; low SHBG increases free fractions and side-effect risk. I tailor dosing accordingly:

• High SHBG: Consider slightly higher initial total testosterone and address contributors (oral estrogens, hyperthyroidism).
• Low SHBG: Start lower to avoid androgenic side effects; treat root causes like insulin resistance or hypothyroidism.

Patients on stimulants or with chronic pain sometimes require higher doses to reach symptom targets, possibly due to altered catecholamine tone or clearance; I titrate carefully and monitor labs.

SSRIs, Libido, and Weight

Reassessing After Hormone Optimization

Many women receive SSRIs for mood or energy issues that are hormonally mediated; weight gain and low libido are common SSRI side effects. After initiating appropriate hormone therapy and with informed consent, I may guide a gradual SSRI taper with written instructions and monitoring, ideally coordinating with the original prescriber. Never stop abruptly. We move in small steps—reducing frequency or halving the dose—and hold at the minimal effective dose if withdrawal occurs or symptoms return (NAMS, 2023).

Follow-Up Strategy

Timing Labs to Pharmacokinetics

To ensure safety and efficacy:

• At 4–5 weeks post-initiation or after a dose change, I recheck total and free testosterone, estradiol, and hematocrit/PSA in men, and consider DHT if androgenic signs appear. Thyroid and ferritin are reviewed when indicated.
• Why 4–5 weeks? Tissue levels and receptor signaling stabilize; earlier labs are at risk of misinterpretation.
• If symptoms persist with suboptimal exposure, I consider small “boosts,” reinforce nutrition and sleep, and re-check in several weeks.

Monitoring, Safety, and Endometrial Protection

Evidence-Informed Follow-Up

• Injectables: Hematocrit/hemoglobin, lipids, PSA for men, plus trough hormone levels at 6–8 weeks after dose changes (Bhasin et al., 2018).
• Pellets: Symptom-led follow-up, periodic mid-cycle labs, and counseling about limited reversibility until pellets dissolve.
• Transdermals: Anchor to symptom relief; standardize sampling to avoid contamination artifacts.
• Women on systemic estrogen: Ensure adequate progesterone opposition unless post-hysterectomy. In cycling women with PMS/PMDD, luteal oral micronized progesterone 100–200 mg at night often improves sleep and reduces anxiety; in perimenopause with irregular cycles, nightly dosing can be more effective.

Integrative Chiropractic Care as a Force Multiplier

Aligning Biomechanics, Autonomics, and Endocrine Health

Hormones do not act in isolation. Mechanical pain and stress feedback into the HPA–HPO axis. I integrate:

• Targeted spinal manipulation: Restores segmental mobility, reduces nociceptive input, and downshifts sympathetic tone, improving sleep architecture and endocrine responsiveness.
• Myofascial release and soft-tissue work: Reduce peripheral sensitization and improve microcirculation, enabling higher-quality training—critical for androgen synergy.
• Neuromuscular rehabilitation: Corrective exercises emphasize gluteal activation, thoracic extension, and breathing mechanics to expand vagal tone and support blood pressure variability.
• Breathing retraining: Slow nasal breathing and resonance frequency breathing improve HRV and reduce hot-flash frequency.
• Anti-inflammatory nutrition: Omega-3s, fiber, phytonutrients, magnesium, and protein distribution improve aromatase balance and reduce cytokine-driven fatigue.

Clinical observations: When thoracic extension and diaphragmatic motion return, patients report fewer nighttime awakenings and improved tolerance to hot flashes within 2–3 weeks. Strength training plus transdermal estradiol and targeted progesterone outperforms hormone therapy alone in bone density proxies and mood stability. Chronic neck/upper back tension lessens menstrual migraines when cervical/thoracic mechanics improve alongside magnesium and omega-3s.

Case Vignettes From Practice

Patterns I See

• An anxious midlife woman with nightly 2:30 AM awakenings, heavy periods, and breast tenderness: labs show low luteal progesterone with variable estradiol. Nightly oral micronized progesterone 100–200 mg improves sleep and irritability within 2–3 weeks; if vasomotor symptoms persist, I add a moderate-dose transdermal estradiol with endometrial protection. Integrative care focuses on myofascial release of cervical/upper thoracic segments and sleep hygiene—rapid gains are common.
• A man in his early 50s with low morning erections, fatigue, and central weight gain: baseline testosterone is low-normal with symptoms. After discussing fertility, we trial micro-dosed subcutaneous injections to smooth peaks, plus strength training and anti-inflammatory nutrition. Follow-up shows improved energy, restored morning erections, and better glycemic control. Manual therapy reduces lumbar pain, enabling consistent training and further metabolic improvements.
• Postmenopausal woman with chronic pain and fibromyalgia phenotype: low estradiol/high FSH, hyperalgesia, and nonrestorative sleep. Transdermal estradiol with oral micronized progesterone, gentle graded loading, and parasympathetic training reduce pain and improve sleep continuity over 8–12 weeks.

Putting It All Together

Personalized, Evidence-Based Roadmaps

I structure care around clear steps:

• Baseline: MRS and AIMS symptom scales; labs drawn on therapy if applicable; explicit menstrual status; musculoskeletal and autonomic assessment.
• Start: Conservative testosterone to prime receptors; low basal estradiol in perimenopause; micronized progesterone for endometrial protection and sleep; foundational nutrients and sleep optimization.
• Monitor: Symptom scales every visit; labs targeting free testosterone, thyroid, ferritin, insulin markers, hs-CRP; track FSH over the medium term.
• Titrate: Small, stepwise increases every 1–2 cycles based on symptoms and safety; do not chase a single lab value—let the patient’s lived experience lead.
• Expand: Consider additional therapies only when fundamentals stabilize; keep documentation crisp and consent explicit for safety.

Why This Works

The Physiology Behind the Protocol

• Gradual receptor conditioning: AR and ER signaling demonstrate nonlinear dose–response behavior. Priming avoids receptor saturation and spikes in adverse metabolites.
• Network integration: Hormones operate within a web—thyroid, insulin, cortisol, and autonomic tone co-determine outcomes. Chiropractic and lifestyle recalibrate the neuroimmune context, enabling hormones to perform constructive work (Chrousos, 2009).
• Objective–behavioral feedback: Validated scales capture the patient’s lived experience; labs capture the biochemical backdrop. Using both creates a precise, humane model that respects complexity without paralysis.

Final Takeaways

What You Should Remember

• Symptoms like anxiety, night awakenings, low libido, and weight resistance are often neuroendocrine in origin. Measure, understand, and correct them thoughtfully.
• Delivery route matters—choose based on physiology, safety, preference, and practicality of monitoring.
• Progesterone is a linchpin for midlife women’s sleep and mood; it protects the endometrium whenever systemic estrogen is used, and the uterus is present.
• Integrating chiropractic care, movement, nutrition, and stress modulation magnifies hormone therapy’s benefits and provides durable outcomes.

---

References

Andersen, M. L., & Tufik, S. (2018). The effects of testosterone on sleep and sleep-disordered breathing in men: Its bidirectional interaction with erectile dysfunction. Sleep Science. https://doi.org/10.5935/1984-0063.20180028

Baker, F. C., de Zambotti, M., Colrain, I. M., & Bei, B. (2018). Sleep problems during the menopausal transition: Prevalence, impact, and management strategies. Nature and Science of Sleep. https://doi.org/10.2147/NSS.S125807

Barrett-Connor, E., Dam, T. T., Stone, K., Harrison, S. L., Redline, S., Orwoll, E., & Osteoporotic Fractures in Men Study Group. (2008). The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-1132

Barth, C., Villringer, A., & Sacher, J. (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2015.00037

Bartley, E. J., & Fillingim, R. B. (2013). Sex differences in pain: A brief review of clinical and experimental findings. British Journal of Anaesthesia. https://doi.org/10.1093/bja/aet127

Bhasin, S., et al. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. https://academic.oup.com/jcem/article/103/5/1715/4939465

Canonico, M., et al. (2016). Postmenopausal hormone therapy and cardiovascular disease: The role of transdermal estradiol. Climacteric. https://doi.org/10.1080/13697137.2015.1121970

Cano, A., et al. (2012). The menopause rating scale (MRS) as outcome measure. Health and Quality of Life Outcomes. https://doi.org/10.1186/1477-7525-10-1

Chrousos, G. P. (2009). Stress and disorders of the stress system. Nature Reviews Endocrinology. https://www.nature.com/articles/nrendo.2009.106

Corona, G., et al. (2012). The relationship between testosterone and erectile function: A systematic review. European Urology. https://doi.org/10.1016/j.eururo.2011.12.010

de Zambotti, M., et al. (2015). Sleep, circadian rhythms, and menopause: Mechanisms and treatment. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2015.05.007

Davis, S. R., & Wahlin-Jacobsen, S. (2015). Testosterone in women—the clinical significance. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213-8587(15)00284-3

Elraiyah, T., et al. (2014). The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2014-2263

Grossmann, M. (2018). Testosterone and glucose metabolism in men. Current Opinion in Endocrinology, Diabetes and Obesity. https://doi.org/10.1097/MED.0000000000000409

Grossman, M., & Wierman, M. (2016). Female androgen deficiency: Recognition and management. Endocrine Practice. https://doi.org/10.4158/EP15922.RA

Iadecola, C., & Yaffe, K. (2020). Bending the curve: Brain health through midlife and beyond. Neuron. https://www.cell.com/neuron/fulltext/S0896-6273(19)31058-7

Islam, R. M., et al. (2019). Safety and efficacy of testosterone for women: A systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213-8587(19)30395-5

Kingsberg, S. A., et al. (2019). Women’s sexual health and the menopause: Pathophysiology and management. The Journal of Sexual Medicine. https://doi.org/10.1016/j.jsxm.2019.01.001

Kresch, E., et al. (2018). Scrotal application of testosterone: Pharmacokinetics and practical considerations. Sexual Medicine Reviews. https://doi.org/10.1016/j.sxmr.2018.05.003

MacGregor, E. A. (2018). Migraine in women. Seminars in Neurology. https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0038-1676847

Mendelsohn, M. E., & Karas, R. H. (2005). Molecular and cellular basis of cardiovascular gender differences. Science. https://www.science.org/doi/10.1126/science.1112062

Morsink, L. F., et al. (2020). Estrogen and adipose tissue: A balance between lipogenesis and lipolysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2020.00258

Naftolin, F., et al. (2019). The science of estrogen therapy and timing hypothesis. Menopause. https://doi.org/10.1097/GME.0000000000001402

NAMS. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. https://journals.lww.com/menopausejournal/Fulltext/2022/07000/The_2022_hormone_therapy_position_statement_of_The.1.aspx

NAMS. (2023). Nonhormone therapy for menopausal vasomotor symptoms. Menopause. https://journals.lww.com/menopausejournal/Fulltext/2023/06000/Nonhormone_therapy_for_menopausal_vasomotor.2.aspx

Parish, S. J., et al. (2021). International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. The Journal of Sexual Medicine. https://doi.org/10.1016/j.jsxm.2021.02.467

Patel, A. S., Leong, J. Y., Ramos, L., & Ramasamy, R. (2019). Testosterone is a contraceptive and should not be used in men who desire fertility. The World Journal of Men’s Health. https://doi.org/10.5534/wjmh.180027

Santoro, N., et al. (2015). The perimenopause: Emerging concepts. Endocrine Reviews. https://academic.oup.com/edrv/article/36/1/1/2354718

Schmidt, P. J., Ben Dor, R., Martinez, P. E., Guerrieri, G. M., Harsh, V., Thompson, K., & Rubinow, D. R. (2015). Effects of estradiol withdrawal on mood in women with past perimenopausal depression. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2015.0483

Schmidt, P. J., et al. (2017). Neurosteroids, GABA, and the menstrual cycle: Implications for anxiety and mood. Molecular Psychiatry. https://doi.org/10.1038/mp.2017.7

Stewart, E. A., et al. (2017). Uterine fibroids. Nature Reviews Disease Primers. https://www.nature.com/articles/nrdp201737

Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. https://academic.oup.com/jcem/article/100/11/3975/2836060

Stute, P., et al. (2016). Micronized progesterone: Evidence-based review of safety and efficacy. Gynecological Endocrinology. https://doi.org/10.1080/09513590.2016.1234545

Thurston, R. C., et al. (2015). Vasomotor symptoms and thermoregulatory physiology. Menopause. https://doi.org/10.1097/GME.0000000000000490

Traish, A. M. (2018). Testosterone and weight loss: The evidence. Current Opinion in Endocrinology, Diabetes and Obesity. https://doi.org/10.1097/MED.0000000000000425